Azithromycin Dosing for Pneumonia
For pediatric community-acquired pneumonia (CAP), use azithromycin 10 mg/kg on day 1, followed by 5 mg/kg once daily on days 2-5 (oral) or 10 mg/kg IV on days 1-2 with transition to oral therapy as soon as possible. For adults with CAP, use 500 mg on day 1, followed by 250 mg once daily on days 2-5.
Pediatric Dosing (>3 months old)
For Atypical Pneumonia (Mycoplasma, Chlamydia)
Oral therapy (preferred):
- Day 1: 10 mg/kg once daily (maximum 500 mg)
- Days 2-5: 5 mg/kg once daily (maximum 250 mg)
- Total course: 5 days 1
IV therapy (severe cases):
- 10 mg/kg once daily on days 1 and 2
- Transition to oral therapy as soon as clinically feasible
- Complete 5-day total course 1
Practical Weight-Based Dosing Tables
The FDA label provides specific volume measurements for oral suspension 2:
5-Day Regimen (Community-Acquired Pneumonia):
- 5 kg: 2.5 mL (½ tsp) day 1, then 1.25 mL (¼ tsp) days 2-5
- 10 kg: 5 mL (1 tsp) day 1, then 2.5 mL (½ tsp) days 2-5
- 20 kg: 5 mL day 1, then 2.5 mL days 2-5 (using 200 mg/5 mL suspension)
- 30 kg: 7.5 mL day 1, then 3.75 mL days 2-5
- ≥50 kg: 12.5 mL day 1, then 6.25 mL days 2-5
Adult Dosing
Community-Acquired Pneumonia (Mild Severity)
Standard 5-day regimen:
- Day 1: 500 mg once
- Days 2-5: 250 mg once daily 2
Alternative 3-day regimen:
- 500 mg once daily for 3 days 2
Clinical Context for Adults
The 2019 ATS/IDSA guidelines recommend azithromycin as part of combination therapy for hospitalized CAP patients (with beta-lactams) or as monotherapy in outpatients without comorbidities when local pneumococcal resistance is <25% 3. However, azithromycin alone is NOT first-line for typical bacterial pneumonia in adults—amoxicillin is preferred for outpatients without comorbidities 3.
Key Clinical Considerations
When to Use Azithromycin
Pediatric indications:
- Suspected atypical pathogens (Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia trachomatis) 1
- Children ≥5 years with CAP where atypical vs. bacterial etiology cannot be distinguished clinically 1
- Can be added to beta-lactam therapy empirically in school-age children 1
Adult indications:
- Outpatients without comorbidities (if local pneumococcal resistance <25%) 3
- Combination with beta-lactam for hospitalized patients 3
- Confirmed or suspected atypical pneumonia 3
Important Caveats
Do NOT use azithromycin monotherapy for:
- Suspected Streptococcus pneumoniae with high-level resistance 1
- Staphylococcus aureus (including MRSA) 1
- Healthcare-associated pneumonia (HCAP)—atypical organisms are rare in this setting 4
Safety monitoring:
- Check baseline ECG in patients at risk for QT prolongation 5
- Azithromycin can prolong QTc interval and cause cardiac arrhythmias 2, 5
- Use caution in severe renal impairment (GFR <10 mL/min)—AUC increases 35% 2
- No dose adjustment needed for mild-moderate renal impairment 2
Duration of Therapy
The 5-day regimen is preferred and best studied 1. While 3-day courses show comparable efficacy in some studies 6, the guidelines emphasize 10-day courses have been most thoroughly evaluated, though shorter courses may be adequate for mild disease 1. The unique pharmacokinetics of azithromycin (prolonged tissue half-life) support shorter regimens 7, 8, but stick with the 5-day course for pediatric CAP as this has the strongest evidence base 1.
Resistance Considerations
Proper dosing is critical to minimize resistance development 1. The guidelines strongly recommend using appropriate dosages to achieve minimal effective concentrations at the infection site 1. Limiting antibiotic exposure and spectrum whenever possible helps reduce resistance selection 1.
Vomiting After Dosing
For pediatric patients who vomit within 30 minutes of a dose, re-dosing at the same total dose has been studied in the single-dose regimen for otitis media, but safety of re-dosing after vomiting has not been established for pneumonia regimens 2. Use clinical judgment—if vomiting occurs shortly after administration, consider re-dosing or switching to IV therapy.